Aquestive Therapeutics (NASDAQ:AQST) PT Raised to $10.00

Aquestive Therapeutics (NASDAQ:AQST) had its price target upped by HC Wainwright from $9.00 to $10.00 in a report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, JMP Securities restated a market outperform rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of Buy and an average price target of $8.67.

Aquestive Therapeutics Trading Down 2.3 %

AQST stock opened at $4.68 on Monday. Aquestive Therapeutics has a 1-year low of $1.25 and a 1-year high of $6.23. The firm has a market cap of $426.06 million, a P/E ratio of -11.14 and a beta of 2.84. The business’s 50 day moving average is $4.31 and its 200-day moving average is $3.68.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Sell-side analysts forecast that Aquestive Therapeutics will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AQST. Vanguard Group Inc. boosted its position in Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after buying an additional 1,353,518 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $1,456,000. Blue Owl Capital Holdings LP lifted its stake in shares of Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after purchasing an additional 265,000 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $594,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $380,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.